Biliverdin reductase-A: A novel drug target for atorvastatin in a dog pre-clinical model of Alzheimer disease

Journal of Neurochemistry

Volumn 120, Issue 1, 2012, Pages 135-146

  Barone, Eugenio ^a,b   Mancuso, Cesare ^b   Di Domenico, Fabio ^a,c   Sultana, Rukhsana ^a   Murphy, M Paul ^d   Head, Elizabeth ^d   Butterfield, D Allan ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b CATHOLIC UNIVERSITY   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alzheimer disease; atorvastatin; biliverdin reductase; cognitive function; oxidative stress

Indexed keywords

AMYLOID BETA PROTEIN; ATORVASTATIN; BETA SECRETASE; BILIVERDIN REDUCTASE A; BRAIN PROTEIN; OXIDOREDUCTASE; PLACEBO; UNCLASSIFIED DRUG;

ADOLESCENT; AGED; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CEREBELLUM; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; FEMALE; LIVER LEVEL; MALE; NONHUMAN; OXIDATIVE STRESS; PARIETAL CORTEX; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; TREATMENT DURATION; UPREGULATION;

ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; BRAIN; CEREBELLUM; COGNITION; DOGS; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOPRECIPITATION; LEARNING; LIVER; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; PARIETAL LOBE; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRROLES; UP-REGULATION;

CANIS FAMILIARIS;

EID: 83755221773     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2011.07538.x     Document Type: Article

References (65)

1. Barone E., Trombino S., Cassano R., Sgambato A., De Paola B., Di Stasio E., Picci N., Preziosi P., and, Mancuso C., (2009) Characterization of the S-denitrosylating activity of bilirubin. J. Cell Mol. Med. 13, 2365-2375.
2. Barone E., Di Domenico F., Cenini G., Sultana R., Coccia R., Preziosi P., Perluigi M., Mancuso C., and, Butterfield D. A., (2011a) Oxidative and nitrosative modifications of biliverdin reductase-a in the brain of subjects with Alzheimer's disease and amnestic mild cognitive impairment. J. Alzheimers Dis. 25, 623-633.
3. Barone E., Cenini G., Di Domenico F., Martin S., Sultana R., Mancuso C., Murphy M. P., Head E., and, Butterfield D. A., (2011b) Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action. Pharmacol. Res. 63, 172-180.
4. Barone E., Di Domenico F., Cenini G., Sultana R., Cini C., Preziosi P., Perluigi M., Mancuso C., and, Butterfield D. A., (2011c) Biliverdin reductase-a protein levels and activity in the brains of subjects with Alzheimer disease and mild cognitive impairment. Biochim. Biophys. Acta 1812, 480-487.
5. Butterfield D. A., and, Lauderback C. M., (2002) Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic. Biol. Med. 32, 1050-1060. (Pubitemid 34603342)
6. Butterfield D. A., Barone E., and, Mancuso C., (2011a) Cholesterol-independent neuroprotective and neurotoxic activities of statins: Perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders. Pharmacol. Res. 64, 180-186.
7. Butterfield D. A., Barone E., Di Domenico F., Cenini G., Sultana R., Murphy M. P., Mancuso C., and, Head E., (2011b) Atorvastatin treatment in a dog preclinical model of Alzheimer disease leads to up-regulation of heme oxygenase-1 and is associated with reduced oxidative stress in brain. Int. J. Neuropsychopharmacol. Published Online doi:.
8. Calabrese V., Sultana R., Scapagnini G., et al. (2006) Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer's disease. Antioxid. Redox Signal. 8, 1975-1986. (Pubitemid 46489625)
9. Calabrese V., Mancuso C., Calvani M., Rizzarelli E., Butterfield D. A., and, Stella A. M., (2007) Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat. Rev. Neurosci. 8, 766-775. (Pubitemid 47462116)
10. Cenini G., Sultana R., Memo M., and, Butterfield D. A., (2008) Effects of oxidative and nitrosative stress in brain on p53 proapoptotic protein in amnestic mild cognitive impairment and Alzheimer disease. Free Radic. Biol. Med. 45, 81-85.
11. Cilla D. D., Jr, Whitfield L. R., Gibson D. M., Sedman A. J., and, Posvar E. L., (1996) Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin. Pharmacol. Ther. 60, 687-695. (Pubitemid 27025917)
12. Conrad C. C., Talent J. M., Malakowsky C. A., and, Gracy R. W., (2000) Post-electrophoretic identification of oxidized proteins. Biol. Proced. Online 2, 39-45.
13. Cotman C. W., and, Head E., (2008) The canine (dog) model of human aging and disease: dietary, environmental and immunotherapy approaches. J. Alzheimers Dis. 15, 685-707.
14. Dore S., Takahashi M., Ferris C. D., Zakhary R., Hester L. D., Guastella D., and, Snyder S. H., (1999) Bilirubin, formed by activation of heme oxygenase-2, protects neurons against oxidative stress injury. Proc. Natl. Acad. Sci. USA 96, 2445-2450. (Pubitemid 29117935)
15. Ewing J. F., Weber C. M., and, Maines M. D., (1993) Biliverdin reductase is heat resistant and coexpressed with constitutive and heat shock forms of heme oxygenase in brain. J. Neurochem. 61, 1015-1023. (Pubitemid 23241240)
16. Feldman H. H., Doody R. S., Kivipelto M., et al. (2010) Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 74, 956-964.
17. Franklin E. M., Browne S., Horan A. M., Inomata K., Hammam M. A., Kinoshita H., Lamparter T., Golfis G., and, Mantle T. J., (2009) The use of synthetic linear tetrapyrroles to probe the verdin sites of human biliverdin-IXalpha reductase and human biliverdin-IXbeta reductase. FEBS J. 276, 4405-4413.
18. Head E., McCleary R., Hahn F. F., Milgram N. W., and, Cotman C. W., (2000) Region-specific age at onset of beta-amyloid in dogs. Neurobiol. Aging 21, 89-96. (Pubitemid 30224790)
19. Head E., Rofina J., and, Zicker S., (2008) Oxidative stress, aging, and central nervous system disease in the canine model of human brain aging. Vet. Clin. North Am. Small Anim. Pract. 38, 167-178 vi. (Pubitemid 351176589)
20. Hsu M., Muchova L., Morioka I., Wong R. J., Schroder H., and, Stevenson D. K., (2006) Tissue-specific effects of statins on the expression of heme oxygenase-1 in vivo. Biochem. Biophys. Res. Co. 343, 738-744.
21. Jick H., Zornberg G. L., Jick S. S., Seshadri S., and, Drachman D. A., (2000) Statins and the risk of dementia. Lancet 356, 1627-1631.
22. Johnstone E. M., Chaney M. O., Norris F. H., Pascual R., and, Little S. P., (1991) Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis. Brain Res. Mol. Brain Res. 10, 299-305.
23. Kandiah N., and, Feldman H. H., (2009) Therapeutic potential of statins in Alzheimer's disease. J. Neurol. Sci. 283, 230-234.
24. Kapitulnik J., and, Maines M. D., (2009) Pleiotropic functions of biliverdin reductase: cellular signaling and generation of cytoprotective and cytotoxic bilirubin. Trends Pharmacol. Sci. 30, 129-137.
25. Kurata T., Miyazaki K., Kozuki M., Panin V. L., Morimoto N., Ohta Y., Nagai M., Ikeda Y., Matsuura T., and, Abe K., (2011) Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice. Brain Res. 1371, 161-170.
26. Lai I. R., Chang K. J., Tsai H. W., and, Chen C. F., (2008) Pharmacological preconditioning with simvastatin protects liver from ischemia-reperfusion injury by heme oxygenase-1 induction. Transplantation 85, 732-738.
27. Lauderback C. M., Hackett J. M., Huang F. F., Keller J. N., Szweda L. I., Markesbery W. R., and, Butterfield D. A., (2001) The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42. J. Neurochem. 78, 413-416. (Pubitemid 32664423)
28. Lerner-Marmarosh N., Shen J., Torno M. D., Kravets A., Hu Z., and, Maines M. D., (2005) Human biliverdin reductase: a member of the insulin receptor substrate family with serine/threonine/tyrosine kinase activity. Proc. Natl. Acad. Sci. USA 102, 7109-7114. (Pubitemid 40696342)
29. Lerner-Marmarosh N., Miralem T., Gibbs P. E., and, Maines M. D., (2008) Human biliverdin reductase is an ERK activator; hBVR is an ERK nuclear transporter and is required for MAPK signaling. Proc. Natl. Acad. Sci. USA 105, 6870-6875. (Pubitemid 351754497)
30. Maines M. D., (2005) New insights into biliverdin reductase functions: linking heme metabolism to cell signaling. Physiology (Bethesda) 20, 382-389. (Pubitemid 41812421)
31. Maines M. D., (2007) Biliverdin reductase: PKC interaction at the cross-talk of MAPK and PI3K signaling pathways. Antioxid. Redox Signal. 9, 2187-2195. (Pubitemid 350059025)
32. Maines M. D., Ewing J. F., Huang T. J., and, Panahian N., (2001) Nuclear localization of biliverdin reductase in the rat kidney: response to nephrotoxins that induce heme oxygenase-1. J. Pharmacol. Exp. Ther. 296, 1091-1097. (Pubitemid 32187386)
33. Mancuso C., and, Barone E., (2009) The heme oxygenase/biliverdin reductase pathway in drug research and development. Curr. Drug Metab. 10, 579-594.
34. Mancuso C., Pani G., and, Calabrese V., (2006) Bilirubin: an endogenous scavenger of nitric oxide and reactive nitrogen species. Redox Rep. 11, 207-213. (Pubitemid 44741627)
35. Mancuso C., Scapagini G., Curro D., Giuffrida Stella A. M., De Marco C., Butterfield D. A., and, Calabrese V., (2007) Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Front. Biosci. 12, 1107-1123. (Pubitemid 46846882)
36. Mancuso C., Capone C., Ranieri S. C., Fusco S., Calabrese V., Eboli M. L., Preziosi P., Galeotti T., and, Pani G., (2008) Bilirubin as an endogenous modulator of neurotrophin redox signaling. J. Neurosci. Res. 86, 2235-2249.
37. Mancuso C., Navarra P., and, Preziosi P., (2010) Roles of nitric oxide, carbon monoxide, and hydrogen sulfide in the regulation of the hypothalamic-pituitary-adrenal axis. J. Neurochem. 113, 563-575.
38. Markesbery W. R., (1997) Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 23, 134-147. (Pubitemid 27217017)
39. McGuinness B., O'Hare J., Craig D., Bullock R., Malouf R., and, Passmore P., (2010) Statins for the treatment of dementia. Cochrane Database Syst. Rev. 8, CD007514.
40. Murphy M. P., Morales J., Beckett T. L., et al. (2010) Changes in cognition and amyloid-beta processing with long term cholesterol reduction using atorvastatin in aged dogs. J. Alzheimers Dis. 22, 135-150.
41. Opii W. O., Joshi G., Head E., Milgram N. W., Muggenburg B. A., Klein J. B., Pierce W. M., Cotman C. W., and, Butterfield D. A., (2008) Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and program of behavioral enrichment: Relevance to Alzheimer's disease. Neurobiol. Aging 29, 51-70. (Pubitemid 350102715)
42. Owen J. B., Sultana R., Aluise C. D., Erickson M. A., Price T. O., Bu G., Banks W. A., and, Butterfield D. A., (2010) Oxidative modification to LDL receptor-related protein 1 in hippocampus from subjects with Alzheimer disease: implications for Abeta accumulation in AD brain. Free Radic. Biol. Med. 49, 1798-1803.
43. Petanceska S. S., DeRosa S., Olm V., Diaz N., Sharma A., Thomas-Bryant T., Duff K., Pappolla M., and, Refolo L. M., (2002) Statin therapy for Alzheimer's disease: will it work? J. Mol. Neurosci. 19, 155-161. (Pubitemid 35013349)
44. Poon H. F., Calabrese V., Scapagnini G., and, Butterfield D. A., (2004) Free radicals: key to brain aging and heme oxygenase as a cellular response to oxidative stress. J. Gerontol. A Biol. Sci. Med. Sci. 59, 478-493. (Pubitemid 38649940)
45. Querfurth H. W., and, LaFerla F. M., (2010) Alzheimer's disease. N. Engl. J. Med. 362, 329-344.
46. Sacktor T. C., (2011) How does PKMzeta maintain long-term memory? Nat. Rev. Neurosci. 12, 9-15.
47. Salim M., Brown-Kipphut B. A., and, Maines M. D., (2001) Human biliverdin reductase is autophosphorylated, and phosphorylation is required for bilirubin formation. J. Biol. Chem. 276, 10929-10934. (Pubitemid 38089271)
48. Shen H. R., Li Z. D., and, Zhong M. K., (2006) HPLC assay and pharmacokinetic study of atorvastatin in beagle dogs after oral administration of atorvastatin self-microemulsifying drug delivery system. Pharmazie 61, 18-20.
49. Smith M. A., Perry G., and, Pryor W. A., (2002) Causes and consequences of oxidative stress in Alzheimer's disease. Free Radic. Biol. Med. 32, 1049. (Pubitemid 34603341)
50. Stern R. H., Yang B. B., Hounslow N. J., MacMahon M., Abel R. B., and, Olson S. C., (2000) Pharmacodynamics and pharmacokinetic-pharmacodynamic relationships of atorvastatin, an HMG-CoA reductase inhibitor. J. Clin. Pharmacol. 40, 616-623.
51. Stocker R., (2004) Antioxidant activities of bile pigments. Antioxid. Redox Signal. 6, 841-849. (Pubitemid 39237937)
52. Stocker R., Glazer A. N., and, Ames B. N., (1987a) Antioxidant activity of albumin-bound bilirubin. Proc. Natl. Acad. Sci. USA 84, 5918-5922. (Pubitemid 17130420)
53. Stocker R., Yamamoto Y., McDonagh A. F., Glazer A. N., and, Ames B. N., (1987b) Bilirubin is an antioxidant of possible physiological importance. Science 235, 1043-1046. (Pubitemid 17049750)
54. Studzinski C. M., Christie L. A., Araujo J. A., Burnham W. M., Head E., Cotman C. W., and, Milgram N. W., (2006) Visuospatial function in the beagle dog: an early marker of cognitive decline in a model of human aging and dementia. Neurobiol. Learn. Mem. 86, 197-204. (Pubitemid 44287579)
55. Subramaniam R., Roediger F., Jordan B., Mattson M. P., Keller J. N., Waeg G., and, Butterfield D. A., (1997) The lipid peroxidation product, 4-hydroxy-2-trans-nonenal, alters the conformation of cortical synaptosomal membrane proteins. J. Neurochem. 69, 1161-1169. (Pubitemid 27364837)
56. Suzuki A., Fukushima H., Mukawa T., et al. (2011) Upregulation of CREB-mediated transcription enhances both short- and long-term memory. J. Neurosci. 31, 8786-8802.
57. Tesco G., Koh Y. H., Kang E. L., et al. (2007) Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity. Neuron 54, 721-737. (Pubitemid 46843521)
58. Thelen K. M., Rentsch K. M., Gutteck U., Heverin M., Olin M., Andersson U., von Eckardstein A., Bjorkhem I., and, Lutjohann D., (2006) Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin. J. Pharmacol. Exp. Ther. 316, 1146-1152. (Pubitemid 43345288)
59. Torp R., Head E., and, Cotman C. W., (2000a) Ultrastructural analyses of beta-amyloid in the aged dog brain: Neuronal beta-amyloid is localized to the plasma membrane. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 24, 801-810. (Pubitemid 30640160)
60. Torp R., Head E., Milgram N. W., Hahn F., Ottersen O. P., and, Cotman C. W., (2000b) Ultrastructural evidence of fibrillar β-amyloid associated with neuronal membranes in behaviorally characterized aged dog brains. Neuroscience 93, 495-506. (Pubitemid 30136315)
61. Torp R., Ottersen O. P., Cotman C. W., and, Head E., (2003) Identification of neuronal plasma membrane microdomains that colocalize beta-amyloid and presenilin: implications for beta-amyloid precursor protein processing. Neuroscience 120, 291-300. (Pubitemid 37288767)
62. Tudor C., Lerner-Marmarosh N., Engelborghs Y., Gibbs P. E., and, Maines M. D., (2008) Biliverdin reductase is a transporter of haem into the nucleus and is essential for regulation of HO-1 gene expression by haematin. Biochem. J. 413, 405-416.
63. Vassar R., Kovacs D. M., Yan R., and, Wong P. C., (2009) The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. J. Neurosci. 29, 12787-12794.
64. Wahle T., Prager K., Raffler N., Haass C., Famulok M., and, Walter J., (2005) GGA proteins regulate retrograde transport of BACE1 from endosomes to the trans-Golgi network. Mol. Cell. Neurosci. 29, 453-461. (Pubitemid 40799217)
65. Walsh K. M., Albassam M. A., and, Clarke D. E., (1996) Subchronic toxicity of atorvastatin, a hydroxymethylglutaryl-coenzyme A reductase inhibitor, in beagle dogs. Toxicol. Pathol. 24, 468-476. (Pubitemid 26274856)